MTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm

Wei Wang,1,2,* Zaoxiu Hu,3,* Mingsheng Ma,4 Haoyuan Yin,4 Yunchao Huang,1 Guangqiang Zhao,1 Xin Cui,1 Qinling Sun,1 Yantao Yang,1 Yichen Yang,1 Biying Wang,1 Lianhua Ye1 1Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, People’s Re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wang W, Hu Z, Ma M, Yin H, Huang Y, Zhao G, Cui X, Sun Q, Yang Y, Wang B, Ye L
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
Acceso en línea:https://doaj.org/article/1ec5f050371e42e9a05a58fa499586a9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1ec5f050371e42e9a05a58fa499586a9
record_format dspace
spelling oai:doaj.org-article:1ec5f050371e42e9a05a58fa499586a92021-12-02T19:17:36ZMTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm1178-203Xhttps://doaj.org/article/1ec5f050371e42e9a05a58fa499586a92021-12-01T00:00:00Zhttps://www.dovepress.com/mta1-expression-can-stratify-the-risk-of-patients-with-multifocal-non--peer-reviewed-fulltext-article-TCRMhttps://doaj.org/toc/1178-203XWei Wang,1,2,* Zaoxiu Hu,3,* Mingsheng Ma,4 Haoyuan Yin,4 Yunchao Huang,1 Guangqiang Zhao,1 Xin Cui,1 Qinling Sun,1 Yantao Yang,1 Yichen Yang,1 Biying Wang,1 Lianhua Ye1 1Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, People’s Republic of China; 2Department of Thoracic Surgery, Taihe Hospital (Hubei University of Medicine), Shiyan, People’s Republic of China; 3Department of Pathology, The Third Affiliated Hospital of Kunming Medical University, Kunming, People’s Republic of China; 4Department of Thoracic Surgery, The Sixth Affiliated Hospital of Kunming Medical University, Yuxi, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lianhua YeDepartment of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, No. 519 Kunzhou Road, Xishan District, Kunming City, Yunnan Province, People’s Republic of ChinaEmail lhye1204@aliyun.comPurpose: Currently, there is no uniform standard to guide postoperative adjuvant chemotherapy for patients with multifocal non-small cell lung cancers (NSCLCs) ≤ 3 cm. Therefore, there is an urgent need to explore prognostic molecular markers to identify high-risk patients with multifocal NSCLCs ≤ 3 cm. We aimed to explore the potential value of metastasis-associated protein 1(MTA1) expression in risk stratification of patients with multifocal NSCLCs ≤ 3 cm.Methods: We retrospectively analyzed the clinical data and postoperative survival data of patients with multifocal NSCLCs ≤ 3 cm. Paraffin-embedded tissue sections were used for immunohistochemistry. Semiquantitative immunoreactivity scoring (IRS) system was used to evaluate the nuclear expression of MTA1. SPSS software (version 23.0) was used to analyze the data.Results: The IRS of MTA1 nuclear expression in 259 lesions of 119 patients ranged from 2.2 to 11.7 (median: 5.6). Our results showed that MTA1 expression was highest in high-risk pathological subtypes of lung adenocarcinoma. MTA1 expression in multiple primary lung cancers (MPLCs) was lower than that in intrapulmonary metastases (IPMs). The median follow-up duration was 25.97 months. The disease-free survival (DFS) of patients with MPLCs was significantly better than that of patients with IPMs, and the DFS of patients with high MTA1 expression was significantly worse than that of patients with low MTA1 expression. Multivariate Cox analysis showed that high MTA1 expression (hazard ratio: 7.937, 95% confidence interval: 2.433– 25.64, p =0.001) was a statistically significant predictor of worse DFS in patients with multifocal NSCLCs ≤ 3 cm.Conclusion: MTA1 expression can stratify the risk in patients with multifocal NSCLCs ≤ 3 cm. Patients with MTA1 immunohistochemical score > 5.6 are at a high risk of postoperative recurrence, and these patients may benefit from postoperative adjuvant chemotherapy.Keywords: multifocal, non-small cell lung cancer, MTA1, multiple primary lung cancers, intrapulmonary metastases, risk of postoperative recurrenceWang WHu ZMa MYin HHuang YZhao GCui XSun QYang YYang YWang BYe LDove Medical Pressarticlemultifocalnon-small cell lung cancermta1multiple primary lung cancersintrapulmonary metastasesrisk of postoperative recurrenceTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 1295-1304 (2021)
institution DOAJ
collection DOAJ
language EN
topic multifocal
non-small cell lung cancer
mta1
multiple primary lung cancers
intrapulmonary metastases
risk of postoperative recurrence
Therapeutics. Pharmacology
RM1-950
spellingShingle multifocal
non-small cell lung cancer
mta1
multiple primary lung cancers
intrapulmonary metastases
risk of postoperative recurrence
Therapeutics. Pharmacology
RM1-950
Wang W
Hu Z
Ma M
Yin H
Huang Y
Zhao G
Cui X
Sun Q
Yang Y
Yang Y
Wang B
Ye L
MTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm
description Wei Wang,1,2,* Zaoxiu Hu,3,* Mingsheng Ma,4 Haoyuan Yin,4 Yunchao Huang,1 Guangqiang Zhao,1 Xin Cui,1 Qinling Sun,1 Yantao Yang,1 Yichen Yang,1 Biying Wang,1 Lianhua Ye1 1Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, People’s Republic of China; 2Department of Thoracic Surgery, Taihe Hospital (Hubei University of Medicine), Shiyan, People’s Republic of China; 3Department of Pathology, The Third Affiliated Hospital of Kunming Medical University, Kunming, People’s Republic of China; 4Department of Thoracic Surgery, The Sixth Affiliated Hospital of Kunming Medical University, Yuxi, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lianhua YeDepartment of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, No. 519 Kunzhou Road, Xishan District, Kunming City, Yunnan Province, People’s Republic of ChinaEmail lhye1204@aliyun.comPurpose: Currently, there is no uniform standard to guide postoperative adjuvant chemotherapy for patients with multifocal non-small cell lung cancers (NSCLCs) ≤ 3 cm. Therefore, there is an urgent need to explore prognostic molecular markers to identify high-risk patients with multifocal NSCLCs ≤ 3 cm. We aimed to explore the potential value of metastasis-associated protein 1(MTA1) expression in risk stratification of patients with multifocal NSCLCs ≤ 3 cm.Methods: We retrospectively analyzed the clinical data and postoperative survival data of patients with multifocal NSCLCs ≤ 3 cm. Paraffin-embedded tissue sections were used for immunohistochemistry. Semiquantitative immunoreactivity scoring (IRS) system was used to evaluate the nuclear expression of MTA1. SPSS software (version 23.0) was used to analyze the data.Results: The IRS of MTA1 nuclear expression in 259 lesions of 119 patients ranged from 2.2 to 11.7 (median: 5.6). Our results showed that MTA1 expression was highest in high-risk pathological subtypes of lung adenocarcinoma. MTA1 expression in multiple primary lung cancers (MPLCs) was lower than that in intrapulmonary metastases (IPMs). The median follow-up duration was 25.97 months. The disease-free survival (DFS) of patients with MPLCs was significantly better than that of patients with IPMs, and the DFS of patients with high MTA1 expression was significantly worse than that of patients with low MTA1 expression. Multivariate Cox analysis showed that high MTA1 expression (hazard ratio: 7.937, 95% confidence interval: 2.433– 25.64, p =0.001) was a statistically significant predictor of worse DFS in patients with multifocal NSCLCs ≤ 3 cm.Conclusion: MTA1 expression can stratify the risk in patients with multifocal NSCLCs ≤ 3 cm. Patients with MTA1 immunohistochemical score > 5.6 are at a high risk of postoperative recurrence, and these patients may benefit from postoperative adjuvant chemotherapy.Keywords: multifocal, non-small cell lung cancer, MTA1, multiple primary lung cancers, intrapulmonary metastases, risk of postoperative recurrence
format article
author Wang W
Hu Z
Ma M
Yin H
Huang Y
Zhao G
Cui X
Sun Q
Yang Y
Yang Y
Wang B
Ye L
author_facet Wang W
Hu Z
Ma M
Yin H
Huang Y
Zhao G
Cui X
Sun Q
Yang Y
Yang Y
Wang B
Ye L
author_sort Wang W
title MTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm
title_short MTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm
title_full MTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm
title_fullStr MTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm
title_full_unstemmed MTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm
title_sort mta1 expression can stratify the risk of patients with multifocal non-small cell lung cancers ≤3 cm
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/1ec5f050371e42e9a05a58fa499586a9
work_keys_str_mv AT wangw mta1expressioncanstratifytheriskofpatientswithmultifocalnonsmallcelllungcancersle3cm
AT huz mta1expressioncanstratifytheriskofpatientswithmultifocalnonsmallcelllungcancersle3cm
AT mam mta1expressioncanstratifytheriskofpatientswithmultifocalnonsmallcelllungcancersle3cm
AT yinh mta1expressioncanstratifytheriskofpatientswithmultifocalnonsmallcelllungcancersle3cm
AT huangy mta1expressioncanstratifytheriskofpatientswithmultifocalnonsmallcelllungcancersle3cm
AT zhaog mta1expressioncanstratifytheriskofpatientswithmultifocalnonsmallcelllungcancersle3cm
AT cuix mta1expressioncanstratifytheriskofpatientswithmultifocalnonsmallcelllungcancersle3cm
AT sunq mta1expressioncanstratifytheriskofpatientswithmultifocalnonsmallcelllungcancersle3cm
AT yangy mta1expressioncanstratifytheriskofpatientswithmultifocalnonsmallcelllungcancersle3cm
AT yangy mta1expressioncanstratifytheriskofpatientswithmultifocalnonsmallcelllungcancersle3cm
AT wangb mta1expressioncanstratifytheriskofpatientswithmultifocalnonsmallcelllungcancersle3cm
AT yel mta1expressioncanstratifytheriskofpatientswithmultifocalnonsmallcelllungcancersle3cm
_version_ 1718376901119049728